Literature DB >> 10770457

Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.

J Ballesteros1, A González-Pinto, A Bulbena.   

Abstract

This article reports a meta-analysis of seven independent studies on the association of tardive dyskinesia with all-cause mortality in psychiatric patients. Most of the studies included provide either small sample sizes or follow-up periods too short to reach a substantive conclusion on their own. In the meta-analysis, the overall odds ratio (OR) was significant when calculated either by the fixed-effects model (OR = 1.4, 95% confidence interval [CI] = 1.2-1.7, p < 0.005) or the random-effects model (OR = 1.4, 95% CI = 1.1-1.8, p < 0.005). There was no overall heterogeneity (Q test = 8.1, df = 7,p = 0.32). The overall estimate changed within study designs (OR = 1.4,p = 0.002 in three prospective controlled studies; OR = 2.2, p = 0.02 in two prospective uncontrolled studies; and OR = 0.9, p = 0.80 in two retrospective controlled studies). It was modified upward when the two most influential studies (one prospective and one retrospective) were removed from the overview (OR = 2.2, 95% CI = 1.4-3.5,p = 0.001; Q test = 0.81, df = 4,p = 0.94). The conclusion of the meta-analysis was that tardive dyskinesia must be considered a weak risk factor in terms of mortality. It remains to be elucidated whether it is a risk factor on its own or just a surrogate for any unknown organic liability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770457     DOI: 10.1097/00004714-200004000-00011

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

1.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

2.  Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV.

Authors:  Anne E Willems; Charlotte L Mentzel; Pieter Roberto Bakker; Jim Van Os; Diederik E Tenback; Petra Gelan; Erna Daantjes; Glenn E Matroos; Hans W Hoek; Peter N Van Harten
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

3.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

4.  Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia.

Authors:  Xiang Yang Zhang; Da Chun Chen; Ling Yan Qi; Fang Wang; Mei Hong Xiu; Song Chen; Gui Ying Wu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

Review 5.  The genetics of drug-related movement disorders, an umbrella review of meta-analyses.

Authors:  Nadine C van der Burg; Asmar F Y Al Hadithy; Peter N van Harten; Jim van Os; P Roberto Bakker
Journal:  Mol Psychiatry       Date:  2020-02-04       Impact factor: 15.992

6.  Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder.

Authors:  P Roberto Bakker; Izaäk W de Groot; Jim van Os; Peter N van Harten
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

Review 7.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 8.  Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; John Rathbone; Yusuke Ogawa; Kiyomi Shinohara; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 9.  Cholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Irina Tammenmaa-Aho; Rosie Asher; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 10.  Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

Authors:  Hany G El-Sayeh; John Rathbone; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.